Cost-Effectiveness of Adjuvant Chemotherapy in the Treatment of Early-Stage Colon Cancer.

[1]  N. Tomita,et al.  Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205. , 2014, European journal of cancer.

[2]  James D. Murphy,et al.  Colon cancer, version 3.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  N. Tomita,et al.  S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial) , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  D. Haller,et al.  Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial , 2014, British Journal of Cancer.

[5]  R. Perera,et al.  Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. , 2013, JAMA.

[6]  O. Alagoz,et al.  Cost-Effectiveness of Adjuvant FOLFOX and 5FU/LV Chemotherapy for Patients with Stage II Colon Cancer , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  D. Shin,et al.  S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. , 2012, The Lancet. Oncology.

[8]  W. Scheithauer,et al.  Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  F. D. De Braud,et al.  Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Petrelli,et al.  Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Maureen A. Smith,et al.  Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. McGhee,et al.  Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement , 2011, BMC Cancer.

[13]  W. Scheithauer,et al.  XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results , 2011, British Journal of Cancer.

[14]  R. Winterhalder,et al.  Self-Reported Compliance with Capecitabine: Findings from a Prospective Cohort Analysis , 2011, Oncology.

[15]  F. D. De Braud,et al.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Conroy,et al.  Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6 , 2011, Oncology.

[17]  M. Buxton,et al.  Does Medicare Have an Implicit Cost-Effectiveness Threshold? , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[18]  J. Maroun,et al.  Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada , 2010 .

[19]  J. Bendell,et al.  Costs Associated with Capecitabine or 5-Fluorouracil Monotherapy after Surgical Resection in Patients with Colorectal Cancer , 2009, Oncology.

[20]  T. Fukuda,et al.  Health utility scores of colorectal cancer based on societal preference in Japan , 2009, Quality of Life Research.

[21]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Fukuda,et al.  Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials , 2009, British Journal of Cancer.

[23]  G. Fountzilas,et al.  XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis , 2009 .

[24]  C. Iacono,et al.  The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine. , 2008, European journal of cancer.

[25]  M. Ychou,et al.  Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting , 2008, Oncology.

[26]  L. Saltz,et al.  Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer , 2007 .

[27]  N. Petrelli,et al.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Kopec,et al.  Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Weinstein,et al.  Cost‐effectiveness analysis of oxaliplatin compared with 5‐fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US , 2007, Cancer.

[30]  S. Paisley,et al.  Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer , 2006, British Journal of Cancer.

[31]  N. Petrelli,et al.  Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  W. Scheithauer,et al.  Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial , 2006, British Journal of Cancer.

[33]  C. Twelves,et al.  A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  K. Schulman.  Medicare and cost-effectiveness analysis. , 2006, The New England journal of medicine.

[35]  P. Catalano,et al.  Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Willke,et al.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[37]  Markus Abt,et al.  Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.

[38]  M. Stauch,et al.  Costs of treatment of colorectal cancer in different settings in Germany , 2004, The European Journal of Health Economics, formerly: HEPAC.

[39]  Daniel J Sargent,et al.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Harlan M Krumholz,et al.  Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.

[41]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[42]  M. Postma,et al.  Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. , 2004, Clinical therapeutics.

[43]  Marc Buyse,et al.  Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Weitzel,et al.  Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. , 2001, European journal of cancer.

[45]  N Urban,et al.  Quality of life in survivors of colorectal carcinoma , 2000, Cancer.

[46]  R. Dittus,et al.  Utility valuations for outcome states of colorectal cancer , 1999, American Journal of Gastroenterology.

[47]  P. Rougier,et al.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J. P. Pignon,et al.  Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.

[49]  H. Rockette,et al.  The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  N. Petrelli,et al.  The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  N. Petrelli,et al.  A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  V. Vaitkevicius,et al.  Comparison of continuously infused 5‐fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma , 1975, Cancer.

[53]  K. Zeuli,et al.  in the US , 2004 .

[54]  H. Wieand,et al.  Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Michael R. Green,et al.  The Modulation of Fluorouracil With Leucovorin in Metastatic Colorectal Carcinoma A Prospective Randomized Phase III Trial , 1990 .

[56]  Emmanuel Mitry,et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.